2015 American Transplant Congress
Robotic Kidney Transplantation With Regional Hypothermia: Results from a Prospective Two-Arm Non-Randomized Controlled Trial (Ideal Phase 2b)
ObjectivesMinimally-invasive approaches to kidney transplantation are up-coming. We recently developed and described a novel technique of robotic KT (RKT) using intra corporeal graft cooling. Here,…2015 American Transplant Congress
Hydrogen Sulfide Restores Protective Capacity of University of Wisconsin Solution During Normothermic Preservation
Organ preservation solution is crucial in mitigating effects of ischemia reperfusion injury (IRI) associated with transplantation. Although University of Wisconsin (UW) solution is ideally suited…2015 American Transplant Congress
Clinical and Radiological Predictors of Transplant Renal Artery Stenosis (TRAS)
Elevated peak systolic velocity (PSV) on Doppler ultrasound at the transplant renal artery (TRA) does not always correlate with true transplant renal artery stenosis (TRAS)…2015 American Transplant Congress
Significant Association Between Foxp3 Gene Polymorphism and Outcomes in HBV-Related Liver Transplant Patients
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Background: Previous studies have demonstrated that CD4+Foxp3+ regulatory T (Treg) cells regulate HBV-related disease progression. The present study investigated the association between Treg cells and…2015 American Transplant Congress
Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results from the HCV-TARGET Multicenter Prospective Observational Study
The safety and efficacy of direct-acting antivirals (DAA) for HCV post-LT remain unknown. METHODS: We describe the safety and efficacy of all oral DAA-therapy for…2015 American Transplant Congress
Changes in Utilization, Discard, and Outcomes Associated With Hepatitis C (+) Donor Livers in the Era of Direct Acting Anti-Retroviral Therapy
Johns Hopkins University, Baltimore, MD.
While 45% of liver candidates are hepatitis C (HCV) (+) and might benefit from an HCV (+) donor liver, only 7.1% receive one, and HCV…2015 American Transplant Congress
The Impact of the New Antivirals Sofosfuvir/Ledipasvir on Liver Transplantation for Hepatitis C Cirrhosis
The approval of potent antiviral therapy (AVT) with sofosfuvir/ledipasvir (sof/ldv) for hepatitis C (HCV) dramatically increased cure rates (SVR) to nearly 100%. A recent prospective…2015 American Transplant Congress
Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Co-Infected Recipients: The “Real World” Experience
End stage liver disease is a frequent cause of mortality in patients with HIV. Though demonstrated in the NIH observational trial, the effectiveness of LT…2015 American Transplant Congress
Post-Liver Transplant Metabolic Syndrome Increases the Risk of Recurrent Fibrosis in Patients With Hepatitis C
Department of Medicine, Columbia University, New York, NY.
Introduction: Post-liver transplant (LT) metabolic syndrome (MS) is common and may impact fibrosis progression in LT recipients with hepatitis C virus (HCV). Methods: All adults…2015 American Transplant Congress
Validation of the Model for End-Stage Liver Disease Score Criteria in Liver Transplantation for Acute Flare Up of Hepatitis B in Non-Cirrhotic Liver
Background: Decision of necessity of urgent liver transplantation for acute flare up of hepatitis B in the patients without cirrhosis is difficult. The MELD score…
American Transplant Congress abstracts